• InterView
• Ibrance can be used regardless of underlying condition in BC
• by Dec 24, 2021 05:48am

• InterView
• KYMRIAH, a good but expensive medicine
• by Eo, Yun-Ho Nov 4, 2021 05:56am

• InterView
• Patients with severe diseases don't really like Mooncare
• by Lee, Jeong-Hwan Oct 28, 2021 05:59am

• InterView
• Merck will “focus on specialty care capabilities"
• by Eo, Yun-Ho Oct 21, 2021 05:14am

• InterView
• "A tenure professor’s calling is in developing a new drug"
• by Sep 17, 2021 05:56am

• InterView
• Leclaza’s ESMO data will determine FDA approval
• by An, Kyung-Jin Sep 15, 2021 06:11am

• InterView
• Treatment-free remission drug for chronic myeloid leukemia
• by Sep 7, 2021 05:53am

• InterView
• “Olumiant provides rapid AD symptom improvement"
• by jung, sae-im Aug 6, 2021 06:04am

• InterView
• MSD "Will care for employees and new drug reimbursement"
• by Eo, Yun-Ho Jul 13, 2021 12:59am

• InterView
• Takeda, “Alunbrig improved both OS and QoL”
• by Jul 8, 2021 05:58am